Quest Diagnostics appoints Benjamin Beauvalot as strategy and M&A chief

Quest Diagnostics (NYSE: DGX) announced the appointment of Benjamin Beauvalot as senior vice president, chief strategy and M&A officer. Beauvalot brings more than two decades of experience in business strategy and transformation, including mergers and acquisitions.

In his new role, Beauvalot will develop the company's growth strategy and lead mergers and acquisitions, strategic partnerships, and integrations. He reports to Jim Davis, chairman, CEO and president, and joins the company's executive leadership team.

Prior to joining Quest Diagnostics, Beauvalot held leadership positions at Danaher Corporation, where he served as vice president and head of business development and strategy for the company's biotechnology and genomics business areas. He also worked at Patheon as vice president of strategy and corporate development and vice president of global business operations before the company's acquisition by Thermo Fisher Scientific in 2017. Additionally, he served as vice president of strategy for Banner Life Sciences.

Beauvalot holds a degree in management and business administration from the Institut de Préparation à l'Administration et à la Gestion in Paris, France.

He replaces Dermot Shorten, who is retiring in the second quarter of 2026 after holding the role since 2008. During his tenure at Quest Diagnostics, Shorten oversaw nearly 80 business combinations and collaborations, including approximately 20 acquisitions of hospital outreach laboratories over the past decade.

"Ben has an extensive track record of delivering successful growth, M&A and transformation strategies for world-class healthcare organizations," Davis said in a statement.

The information is based on a company press release statement.

You May Also Be Interested In

• Hackers targeted US private equity, other firms including Blackstone, CME - Reuters
• Etsy (ETSY) PT Raised to $80 at Piper Sandler
• Nvidia Weighs Less Rubin Ultra Chip Memory - Information